Wockhardt LimitedNSE: WOCKPHARMA

Press Release Dec 31 2025

· Issued by Wockhardt Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

The drug has completed a pivotal Phase III clinical trial and has applications pending with regulatory authorities in multiple regions. Wockhardt's ongoing commitment to antibiotic innovation is highlighted by its extensive drug discovery portfolio targeting resistant infections.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Wockhardt Limited on 6ix

Earlier from Wockhardt

Later from Wockhardt

All Wockhardt news releases